Forest Laboratories, Inc.

Overview

Forest Laboratories, Inc. was a pharmaceutical company focused on the development, manufacturing, and sale of branded forms of ethical drug products, which require a physician's prescription. It is now a subsidiary of Allergan Inc. after the acquisition in 2014.

Therapeutic areas

API / Drug Master Files

Forest Laboratories, Inc. holds 53 active (73 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • CAPIVASERTIBActive2026-01-12
  • ZAVEGEPANT HYDROCHLORIDEActive2025-11-28
  • PITAVASTATIN CALCIUM HYDRATEActive2025-09-30
  • ABEMACICLIBActive2025-01-24
  • DOTA (Tetraxetan)Active2022-07-22
  • GADOBUTROL MONOHYDRATEActive2021-12-30
  • FERRIC CARBOXYMALTOSEActive2020-12-31
  • ERIBULIN MESYLATEActive2020-11-30
  • IMATINIB MESYLATEActive2020-10-20
  • ELAGOLIX SODIUMActive2020-06-30
  • RUCAPARIB CAMSYLATEActive2019-12-26
  • GADOTERATE MEGLUMINEActive2019-09-12
  • PATIROMER SORBITEX CALCIUMActive2019-06-06
  • CALCIFEDIOLActive2019-05-03
  • NINTEDANIB ESYLATEActive2018-04-02

Showing 15 of 73 Drug Master Files.

FDA compliance signals

1 FDA enforcement record linked to this company.

  • recall — Class II2017-06-07

    Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.